Back to search results

Personalized Vaccine for High-Risk Liver Cancer (HCC)

This study is testing a personalized vaccine called GNOS-PV02 along with INO-9012, a plasmid (a small piece of DNA) that helps the immune system, in people with high-risk hepatocellular carcinoma (HCC), a type of liver cancer. You might be able to join if you are at least 18 years old, have a confirmed diagnosis of HCC that has been removed by surgery, and have a good liver score (Child-Pugh Class A). The study aims to see if this treatment can help prevent the cancer from coming back (recurrence-free survival) over a period of up to 5 years. The current recruitment status is unclear.

Study design
This is a randomized, open-label (meaning you and your doctors will know which treatment you are receiving), multi-site Phase II study planning to enroll 90 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for recurrence-free survival for up to 5 years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07722741

Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

Recruiting
PHASE2Ages 18+InterventionalTreatment
Geneos Therapeutics
~90 participants
Updated 2026-09-04 on ClinicalTrials.gov
What's tested:GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporationElectroporation DeviceINO-9012

At a glance

Recruiting sites
4 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Recurrence-free survival
Measured over Up to 5 years

Conditions

HCC

Explore related trials

Hepatocellular Carcinoma

NCT07722741

Where you'd take part

This study runs at 8 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Auckland City Hospital (Te Toka Tumai)

    Auckland, New Zealandstudy coordinator listed

    Recruiting

  • Emory University

    Atlanta, Georgiastudy coordinator listed

    Not yet recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washingtonstudy coordinator listed

    Not yet recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New Yorkstudy coordinator listed

    Recruiting

  • Johns Hopkins University

    Baltimore, Marylandstudy coordinator listed

    Recruiting

  • Louisiana State University Health Sciences Center

    New Orleans, Louisianastudy coordinator listed

    Recruiting

  • MD Anderson Cancer Center

    Houston, Texasstudy coordinator listed

    Not yet recruiting

  • University of Michigan

    Ann Arbor, Michiganstudy coordinator listed

    Not yet recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Joann Peters, MHA
[email protected]
434-825-2551
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Recurrence-free survivalUp to 5 years

    RFS is defined as the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary HCC, as assessed by the investigator, or death due to any cause, whichever occurs first.